- Earlier this month, Colgate-Palmolive’s Colgate Optic White brand launched its new Optic White Pro Series Toothpaste in the US, featuring a 5% Hydrogen Peroxide Complex formula, Dual Whitening Technology, and ActivShine Technology, with a US$9.99 MSRP and four variants aimed at at-home whitening.
- This launch highlights Colgate-Palmolive’s push into higher-value, science-backed premium oral care, targeting consumers seeking professional-style whitening results without leaving home.
- Next, we’ll examine how this premium Optic White Pro Series launch fits into Colgate-Palmolive’s existing investment narrative around innovation and premiumization.
AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
Colgate-Palmolive Investment Narrative Recap
To own Colgate-Palmolive, you need to believe in its ability to defend and extend its brands through innovation and premiumization, while managing cost pressures and private label competition. The Optic White Pro Series launch reinforces that premium oral care focus but is unlikely to materially change the near term picture, where rising raw material and packaging costs and their impact on margins remain a key risk to watch.
Among the latest announcements, the small increase in the quarterly dividend to US$0.53 per share stands out as most relevant here, as it signals ongoing confidence in cash generation even as Colgate invests behind premium oral care launches like Optic White Pro Series. For investors, that balance between funding innovation and maintaining consistent shareholder returns sits at the heart of the current catalyst story.
But while premium launches and dividend growth can look reassuring, investors should still be aware of the pressure that higher input costs could...
Read the full narrative on Colgate-Palmolive (it's free!)
Colgate-Palmolive's narrative projects $22.4 billion revenue and $3.5 billion earnings by 2028. This requires 3.8% yearly revenue growth and about a $0.6 billion earnings increase from $2.9 billion today.
Uncover how Colgate-Palmolive's forecasts yield a $97.21 fair value, a 14% upside to its current price.
Exploring Other Perspectives
Five fair value estimates from the Simply Wall St Community span roughly US$78 to US$125 per share, underscoring how far apart individual views can be. As you weigh those perspectives against Colgate-Palmolive’s push into higher priced, science based oral care, consider how rising raw material and packaging costs might shape the company’s ability to defend margins over time.
Explore 5 other fair value estimates on Colgate-Palmolive - why the stock might be worth as much as 47% more than the current price!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your Colgate-Palmolive research is our analysis highlighting 3 key rewards and 3 important warning signs that could impact your investment decision.
- Our free Colgate-Palmolive research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Colgate-Palmolive's overall financial health at a glance.
Want Some Alternatives?
Our top stock finds are flying under the radar-for now. Get in early:
- Explore 24 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
- The best AI stocks today may lie beyond giants like Nvidia and Microsoft. Find the next big opportunity with these 21 smaller AI-focused companies with strong growth potential through early-stage innovation in machine learning, automation, and data intelligence that could fund your retirement.
- Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 28 best rare earth metal stocks of the very few that mine this essential strategic resource.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com